Positron emission tomography (PET) and [F-18]-fluorodeoxyglucose (FDG) in cancerology;Tomographie par émission de positons (TEP) et [F-18]-fluorodésoxygIucose (FDG) en cancérologie

Bulletin du Cancer

Volumn 85, Issue 11, 1998, Pages 935-950

  Maublant, Jean ^a   Vuillez, Jean Philippe ^b   Talbot, Jean Noël ^c   Lumbroso, Jean ^d   Muratet, Jean Pierre ^e   Herry, Jean Yves ^f   Artus, Jean Claude ^g  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL TENON   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d DIF   (France)

^e CENTRE PAUL PAPIN   (France)

^f CENTRE EUGÈNE MARQUIS   (France)

^g CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; GLUCOSE; RADIOPHARMACEUTICAL AGENT;

CANCER LOCALIZATION; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ESOPHAGUS CANCER; HUMAN; IMAGE QUALITY; ISOTOPE LABELING; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; REVIEW; SKIN CANCER; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIGESTIVE SYSTEM TUMOR; FEMALE; GLYCOLYSIS; LUNG TUMOR; LYMPHOMA; MALE; METABOLISM; NEOPLASM; SCINTISCANNING;

DIGESTIVE SYSTEM NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLYCOLYSIS; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MALE; NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032196075     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Warburg O. The metabolism of tumors. In : Smith RR, ed. New York, 1931 ; 129-69.
2. GallagherBM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolie trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy2-fluoro-D-glucose./M(rMfe/1978; 19: 1154-61.
3. Board M, Humm S, Newsholme EA. Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem J 1990 ; 265 : 503-9.
4. Miralpeix M, Azcon-Bieto J, Bartrons R, Argiles JM. The impairment of respiration by glycolysis in the Lewis lung carcinoma. Cancer Lett 1990; 50: 173-8.
5. Mathupala SJ, Rempel A, Pedersen PL. Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem 1995 ; 270 : 16918-25.
6. Vora S, Halper JP, Knowles DM. Alterations in the activity and isozymic profile of human phosphofructokinase during malignant transformation in vivo and in vitro : transformation- and progression-linked discriminants of malignancy. Cancer Res 1985 ; 45 : 2993-3001.
7. Eigenbrodt E, Gerbracht U, Mazurek S, Presek P, Friis R. Carbohydrate metabolism and neoplasia : new perspectives for diagnosis and therapy. In : Biochemical and molecular aspects of selected cancers. Academic Press, 1994:311-85.
8. Ibsen KM, Orlando RA, Garatt KN, Hernandez AM, Giorlando S, Nungaray G. Expression of multimolecular forms of pyruvate kinase in normal, benign, and malignant human breast tissue. Cancer Res 1982 ; 42: 888-92.
9. Nelson JAS, Falk RE. The efficacy of phloridzin and phloretin on tumor cell growth. Anticancer Res 1993 ; 13 : 2287-92.
10. Farnes JR, Isselbacher KJ. Transport alterations in virus-transformed cells. Prog Exp Tumor Res 1978 ; 22 : 79-122.
11. Hume DA, Weidemann MJ. Role and regulation of glucose metabolism in proliferating cells. J Nat! Cancer Inst 1979 ; 62 : 3-8.
12. Merrall N\V, Plevin R, Gould GW. Mini review : growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal 1993 ; 5 : 667-75.
13. Brown RS, Wahl R. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993 ; 72: 2979-85.
14. Mellanen P, Minn H, Grenman R, Härkönen P. Expression of glucose transporters in head-and-neck tumors. IntJ Cancer 1994 ; 56 : 622-9.
15. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyre glucose transporter Glutl in human cancers. Cancer Res 1996 ; 56 : 1164-7.
16. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science 1987: 1495-8.
17. Watanabe A, Tanaka R, Takeda N, Washiyama K. DNA synthesis, blood flow, and glucose utilization in experimental rat brain tumors. JNeurosurg 1989 ; 70 : 86-91.
18. Mazurek S, Hugo F, Failing K, Eigenbrodt E. Studies on associations of glycolytic and glutaminolytic enzymes in MCF-7 cells : role of P36. JCellPlrjsiol 1996 ; 167 : 238-50.
19. Godwin AK, Lieberman MW. Early and late responses to induction of rasT24 expression in rat-1-cells. Oncogene 1990 ; 5 : 1231-41.
20. Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, InokumaT, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997 ; 38 : 1337-44.
21. Reske SN, Grillenberger KG, Glatting G, Port M, Hildebrandt M, Gansauge F, et al. Overexpression of glucose transporter and increased FDG uptake in pancreatic carcinoma. J Nticl AfeJ 1997 ; 38 : 1344-8.
22. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging : a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988 ; 61 : 1776-81.
23. Haberkorn U, Strauss LG, Reisse C, Haag D, Dimitrakopoulou A, . Ziegler S, et al. Glucose uptake, perfusion, and cell proliferation in head ï and neck tumors : relation of positron emission tomography to flow cytomzirf. J Nticl Med 1991 ; 32 : 1548-55.
24. Oriuchi N, Tomiyoshi K, Inoue T, Ahmad K, Sarwar M, TokunagaM, et al. Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma. J Nucl Med 1996 ; 37: 457-62.
25. Minn H, Kangas L, Knuutila V, Paul R, Sipilä H. Determination of 2-fluoro-2-deoxy-D-glucose uptake and ATP level for evaluating drug effects in neoplastic cells. Res Exp Med 1991 ; 191 : 27-35.
26. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Mcd 1993 ; 34 : 414-9.
27. Kubota R, Kubota K, Yamada S, Tada M, Takahashi T, Iwata R, et al. Methionine uptake by tumor tissue : a microautoradiographic comparison with FDG. J Nucl Med 1995 ; 36 : 484-92.
28. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL, et al. Intratumoral distribution of tritiated-FDG in breast carcinoma : 1. Are i inflammatory cells important? J Nucl Med 1995 ; 36 : 1854-61.
29. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N, et al. t Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 1994 ; 35 : 104-12.
30. Haberkorn U, Altmann A, Morr I, Germann C, Oberdorfer F, van Kaick G. Multitracer studies during gene therapy of hepatoma cells with herpes simplex virus thymidine kinase and ganciclovir./ArBfJ.A/tt/1997; j 38 : 1048-54.
31. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, IdoT. J Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo : high i accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992 ; 33 : 1972-80.
32. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in I human cancer cell lines is increased by hypoxia. J Nucl Med 1995 ; 36 : 1625-32.
33. Clavo AC, Wahl RL. Effects of hypoxia on the uptake of tritiated I thymidine, L-leucine, L-methionine and FDG in cultured cancer cells. ! JNucl Med 1996 ; 37 : 502-6.
34. Haberkorn U, Morr I, Oberdorfer F, Bellemann ME, Blatter], Altmann A, et al. Fluorodeoxyglucose uptake in vitro : aspects of methods and effects of treatment with gemcitabine. J Nucl Med 1994 ; 35 : 184250.
35. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur] Nucl Med 1996 ; 23 : 1641-74.
36. Khouri NF, Meziane MA, Zerhouni EA, Fishman EK, Siegelman SS. The solitary pulmonary nodule : assessment, diagnosis and management. Chest 1987:91 : 128-33.
37. Kazerooni EA, Lim FT, Mikhail A, Martinez FJ. Risk of pneumothorax in CT-guided transthoracic needle aspiration biopsy of the lung. Radiology 1996; 198:371-5.
38. Dewan NA, Shehan CJ, Reeb SD, Gobar LS, Scott WJ, Ryschon K. Likelihood of malignancy in a solitary pulmonary nodule : comparison of Bayesian analysis and results in FDG-PET scan. Chest 1997 ; 112 : 416-22.
39. WebbWR, Gatsonis C, Zeerhouni EA, Heelan RT, Glazer GM, Francis IR, et al. CT and MR imaging in staging non-small cell bronchogenie carcinoma: report of the Radiological Diagnostic Oncology Group. Radiology 1991 ; 178:705-13.
40. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan : a prospective study on 690 lymph node stations from 68 patients. J Clin Oiicol 1998 ; 16 : 2142-9.
41. Steinert HC, Hauser M, Allemann F, Engel H, Berthold T, von Schulthess GK, et al. Non-small cell lung cancer nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997 ; 202 : 441-6.
42. Kirn BT, Kim Y, Lee KS, Yoon SB, Cheon EM, Kwon OJ, et al. Localized form of bronchioloalveolar carcinoma : FDG PET findings. Am J Roentgenol 1998 ; 170 : 935-9.
43. Erasmus JJ, McAdams HP, Patz EF Jr, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. Am J Roentgenol 1998 ; 170 : 1369-73.
44. Kiffer JD, Berlangieri SU, Scott AM, Quong G, Feigen M, SchumerW, ft al. The contribution of F-18-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 1998 ; 19 : 167-77.
45. Dewan NA, Reeb SD, Gupta NC, Gobar LS, Scott WJ. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest 1995 ; 108: 441-6.
46. GambhirSS, Hoh CK, Phelps ME, Madar I, MaddahiJ. Decision tree sensitivity analysis for cost-effectiveness of PET-FDG in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996 ; 37: 1428-36.
47. Yonekura Y, Benua RS, Brill AB, Som P, Yeh SD, Kemeny NE, et al. Increased accumulation of 2-deoxy-2-(F18)fluoro-D-glucose in liver métastases from colon carcinoma. J Nucl Med 1982 ; 23 : 1133-7.
48. Schiepers C, Penninckx F, de Vadder N, Merckx E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer : comparison with conventional imaging. Eur J Surg Oncol 1995; 21 : 517-22.
49. Strauss LG, Glorius JH, Schlag, Lehner B, Kimmig B, Engenhart R, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989 ; 170: 329-32.
50. Bury T, Dowlati A, Paulus P, CorhayJL, BenoitT, KayembeJM, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur ResfirJ 1996 ; 9 : 410-4.
51. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998 ; 227 : 319-23.
52. Abdel Nabi H, Doerr RJ, Lamonica DM, Cronin VR, GalantowiczPJ, Carbone GM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998 ; 206 : 75560.
53. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign 15 malignant hepatic lesions with positron emission tomography. Arch Surg 1998 ; 133 : 510-5.
54. Inokuma T, Tamaki N, Torizuka T, Magata Y, Fuji! M, Yonekura Y, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose : comparison with CT and US. Radiology 1995 ; 195 : 345-52.
55. Nakata B, Chung YS, Nishimura S, Nishihara T, Sakurai Y, SiwadaT, et al. F-18-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 1997 ; 79 : 695-8.
56. Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1998; 39: 1002-7.
57. Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti T, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997 ; 64 : 770-6.
58. KeyesJW Jr, Watson NE Jr, Williams DW III, Greven KM, McGuirt WF. FDG PET in head and neck cancer. Am J Roentgenol 1997; 169: 1663-9.
59. McGuirt WF, Greven KM, Keyes JW Jr, Williams DW III, Watson N. Laryngeal radionecrosis versus recurrent cancer : a clinical approach. Ann Otol Rliinol Laryngol 1988 ; 107 : 293-6.
60. McGuirt WF, Greven K, Williams D III, Keyes JW Jr, Watson N, Cappellari JO, et al. PET scanning in head and neck oncology : a review. Head Neck 1998 ; 20 : 208-15.
61. Kubota K, MatsuzawaT, AmeniyaA, Kondo M, FujiwaraT, Watanuki S, et al. Imaging of breast cancer with (F-18) fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989 ; 13 : 1097-100.
62. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma : initial clinical evaluation with PET with the radiolabeled glucose analog 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiolog 1991 ; 179 : 765-70.
63. Hubner KF, Smith GT, Buonocore E. The potential of F-18-PET for the management of patients with breast cancer. J Nucl Med 1997 ; 38 : 69 p. (resume).
64. Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, Shishikura T, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro [F-18]-D-glucose. Cancer 1988 ; 82 : 2227-34.
65. Moon DH, MaddahiJ, Silverman DH, GlaspyJA, Phelps ME, HohCK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent and metastatic breast carcinoma. J Nucl Med 1998 ; 39: 431-5.
66. Avril N, DoseJ, Janicke F, Ziegler S, Römer \V, WeberW, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Nad Cancer Inst 1996 ; 88 : 1204-9.
67. Buscombe JR, CwiklaJB, Thakrar DS, Hilson AJ. Scintigraphic imaging of breast cancer : a review. Nucl Med Comm 1997 ; 18 : 698-709.
68. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langström B, Bergh J, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer : a method for early therapy evaluation. J Clin Oncol 1995 ; 13 : 1470-7.
69. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11:2101-11.
70. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987 ; 28 : 288-92.
71. Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Söderström KO, et al. Increased glucose metabolism in untreated non Hodgkin lymphoma : a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995 ; 86 : 3522-7.
72. Paulus P, Hustinx R, Daenen F, Jacquet N, Rigo P. Usefulness of 18-FDG positron emission tomography in detection and follow-up of digestive cancers. Acta Gastroenterol Belg 1997 ; 60 : 278-80.
73. Carr R, Barrington SF, Madan B, O'Doherty MJ, Saunders CA, van der \Valt J, et aL Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998 ; 91 : 3340-6.
74. Dimitrakopoulou-Strauss A, Strauss LG, Goldsmith H. Evaluation of tumor metabolism and multidrug resistance in patients with malignant lymphoma. EiirJNuclMed 1994 ; 21 : 727 (resume).
75. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma métastases. Ann Stirg 1998 ; 227 : 764-9.
76. MacFarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[F-18]-2-deoxy-D-gIucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998 ; 16 : 1770-6.
77. Ricci PE, KarisJP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography ? Am J Neitroradiol 1998 ; 19 : 407-13.
78. Conti PS, Wdowozyk J, Grafion ST. Improved detection of locally recurrent and metastatic thyroid cancer in patients with persistently elevated thyroglobulin using FDG PET scanning (résumé). EUT JNitdMed1994 ; 21 : S10.
79. Hanke JP, Feine U, Lietzenmayer X. Whole body 18-F-fluorodeoxyglucose PET in 24 patients with differenciated thyroid cancer -flip-flop behavior in uptake patterns of FDG and 1-131 (résumé). EurJ Nucl Med 1995; 23: 769 p.
80. SissonJC, Ackermann RJ, Meyer MA, Wahl RL. Uptake of F-18fluoro-2-deoxy-D-gIucose by thyroid cancer : implications for diagnosis and therapy. J Clin Encrinol Metab 1993 ; 77 : 1090-4.
81. Musholt TJ, Musholt PB, Dehdashti F, Moley JF. Evaluation of fiuorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma : a clinical and molecular study. Surgery 1997; 122 : 1049-60.
82. Kole AC, Nieweg OE, Prium J, Hoekstra HJ, Koops HS, RoodenburgJL, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998 ; 82 : 1160-6.
83. Shreve PD, Steventon RS, Deters EC, Kison PV, Gross MD, WahlRL. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-Dglucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 1998 ; 207 : 431-7.
84. Grahek D, Montravers F, Ghazzar N, Ait Ben Ali S, Younsi N, Kerrou K, etal. Assessment of pulmonary nodule and colorectal cancer recurrences by FDG scan on an ordinary coincidence gamma camera (CDET). Ear] Nucl Med 1998 ; 25 : S 11 (résumé).